ClinicalTrials.gg
RecruitingNCT07668388Updated Oct 7, 2026

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

A Phase 2 interventional study of UBT251 and UBT251 Placebo in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Recruiting at 70 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 7, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S — 25 open to participants now, 29 under way, 11 of them phase 3. Diabetes Mellitus, Type 2 · Novo Nordisk A/S.

Planned enrollment
170th of 428
300 · median 209
Started
2026
with 22 others
Phase 2
37 of 643
2 open now
Primary completion
2027-10
later than 9 of 28 live
Registered
633rd of 643
by date

Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 170th largest by planned enrollment of the 428 interventional ones that give a count, is one of 23 that started in 2026, is one of 37 in phase 2, reaches primary completion later than 9 of the 28 other live ones, and was the 633rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

25 of the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatment participants get is decided by chance. UBT251 is the treatment being tested and is not yet available for doctors to prescribe, while semaglutide is a medicine used to treat type 2 diabetes that doctors can already prescribe.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (sex assigned at birth, inclusive of all gender identities).
  • Age 18-75 years (both inclusive) at the time of signing the .
  • Diagnosed with type 2 diabetes greater than or equal to (≥) 180 days before screening.
  • Stable daily dose(s) ≥ 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator:

metformin with or without sodium-glucose cotransporter-2 (SGLT2) inhibitor.

  • of 7.0-10.5 percent (%) (53-91 millimoles per mole (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
  • between 25.0 kg/m\^2 and 50.0 kg/m\^2 (both inclusive) at screening.

Exclusion criteria

Exclusion Criteria:

  • Treatment with any medication (prescription or over-the counter) or alternative remedies for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire, question 8.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    UBT251

    Participants will receive once weekly UBT251 subcutaneously.

    Drug: UBT251

  • Placebo comparator
    UBT251 Placebo

    Participants will receive once weekly UBT251 placebo subcutaneously.

    Drug: UBT251 Placebo

  • Active comparator
    Semaglutide

    Participants will receive once weekly semaglutide subcutaneously.

    Drug: Semaglutide

  • Placebo comparator
    Semaglutide Placebo

    Participants will receive once weekly semaglutide placebo subcutaneously.

    Drug: Semaglutide Placebo

Interventions

  • DrugUBT251

    UBT251 will be administered subcutaneously once-weekly.

  • DrugUBT251 Placebo

    UBT251 placebo will be administered subcutaneously once-weekly.

  • Semaglutide will be administered subcutaneously once-weekly.

  • DrugSemaglutide Placebo

    Semaglutide placebo will be administered subcutaneously once-weekly.

06

What researchers measure

Primary outcomes

  1. UBT251: Change in glycated haemoglobin (HbA1c)

    Measured as percentage (%)-point.

    Time frame: From baseline (week 0) to 12 weeks on a given maintenance dose (week 16, 28 and 40)

Secondary outcomes

  1. UBT251: Relative change in body weight

    Measured as %.

    Time frame: From baseline (week 0) to week 40

  2. UBT251: Change in body weight

    Measured as kilogram (kg).

    Time frame: From baseline (week 0) to week 40

  3. UBT251 vs placebo: Change in HbA1c

    Measured as %-point.

    Time frame: From baseline (week 0) to 12 weeks on a given maintenance dose (week 16, 28 and 40)

  4. Change in HbA1c

    Measured as %-point.

    Time frame: From baseline (week 0) to week 40

  5. Change in homeostasis model assessment of insulin resistance (HOMA2-IR)

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to week 40

  6. Change in homeostasis model assessment of beta-cell function (HOMA2-B)

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to week 40

  7. Change in fasting plasma glucose (FPG)

    Measured as millimoles per litre (mmol/L).

    Time frame: From baseline (week 0) to 12 weeks on a given maintenance dose (week 16, 28 and 40)

  8. CGM: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 milligrams per deciliter (mg/dL))

    Measured as %-points.

    Time frame: From baseline (week -2 to week 0) to week 14- 16, week 26-28 and week 38-40, respectively

  9. UBT251 vs placebo: Relative change in body weight

    Measured as %.

    Time frame: From baseline (week 0) to week 40

  10. UBT251 vs placebo: Change in body weight

    Measured as kg.

    Time frame: From baseline (week 0) to week 40

  11. Change in body mass index (BMI)

    Measured as Kilograms per square meter (kg/m\^2).

    Time frame: From baseline (week 0) to week 40

  12. Change in waist circumference

    Measured as centimeter (cm).

    Time frame: From baseline (week 0) to week 40

  13. Change in waist-to-height ratio (WHtR)

    Time frame: From baseline (week 0) to week 40

  14. Change in systolic blood pressure (SBP)

    Measured as millimetres of mercury (mmHg).

    Time frame: From baseline (week 0) to week 40

  15. Change in diastolic blood pressure (DBP)

    Measured as mmHg.

    Time frame: From baseline (week 0) to week 40

  16. Change in pulse rate

    Measured in beats/min.

    Time frame: From baseline (week 0) to week 40

  17. Change in high sensitivity C-Reactive Protein (hsCRP)

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to week 40

  18. Change in total cholesterol

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to week 40

  19. Change in high-density lipoprotein (HDL) cholesterol

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to week 40

  20. Change in low-density lipoprotein (LDL) cholesterol

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to week 40

  21. Change in triglycerides

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to week 40

  22. Change in urine albumin creatinine ratio (UACR)

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to 12 weeks on a given maintenance dose (week 16, 28 and 40)

  23. Change in eGFR (creatinine-cystatin C-based CKD-EPI 2021)

    Measured in milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2).

    Time frame: From baseline (week 0) to week 40

  24. Number of treatment-emergent adverse events (TEAEs)

    Measured as number of events.

    Time frame: From baseline (week 0) to week 46

07

Study locations

58 of 70 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Oct 2027, 15 months after the start.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's planned 15 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2026
First posted
Jun 25, 2026
StartActual
Jun 22, 2026
Primary completionEst.
Oct 4, 2027
CompletionEst.
Nov 15, 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites changed recruiting status (5 now recruiting)
Show 5 sites
  • Novatrials · Charlestown, AustraliaNot yet recruiting→Recruiting
  • Semmelweis Egyetem · Budapest, HungaryNot yet recruiting→Recruiting
  • Pécsi Tudományegyetem ÁOK · Pécs, HungaryNot yet recruiting→Recruiting
  • 1 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ · Lublin, PolandNot yet recruiting→Recruiting
  • H. Univ. Marqués de Valdecilla_Endocrinología · Santander, SpainNot yet recruiting→Recruiting
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    5 sites changed recruiting status (5 now recruiting)
    Show 5 sites
    • Novatrials · Charlestown, AustraliaNot yet recruiting→Recruiting
    • Semmelweis Egyetem · Budapest, HungaryNot yet recruiting→Recruiting
    • Pécsi Tudományegyetem ÁOK · Pécs, HungaryNot yet recruiting→Recruiting
    • 1 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ · Lublin, PolandNot yet recruiting→Recruiting
    • H. Univ. Marqués de Valdecilla_Endocrinología · Santander, SpainNot yet recruiting→Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07668388
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 25, 2026
Start date
Jun 22, 2026
Primary completion
Oct 4, 2027 (estimated)
Completion
Nov 15, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: UBT251

Start the discussion